Memorial Sloan-Kettering’s Bach Balks At Drug Pricing
This article was originally published in The Pink Sheet Daily
Executive Summary
Peter Bach slammed the industry over high drug prices and practices such as rebating, which he said confound open debate about drug cost and benefit, during a panel discussion at the BIO CEO & Investor conference.
You may also be interested in...
Role Of Cost And Evidence In Value-Based Purchasing Highlighted By Zaltrap Price Adjustment
Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.